UnitedHealthcare’s March 1, 2026 update consolidates medical necessity criteria for enzyme replacement therapies used in lysosomal storage disorders with pulmonary involvement (Aldurazyme, Elaprase, Lamzede, Mepsevii, Xenpozyme). Coverage requires diagnostic confirmation by enzyme assay or molecular genetic testing plus relevant clinical signs or symptoms, and dosing must follow FDA labeling. Initial and continuation authorizations are limited to a maximum of 12 months; continuations require prior receipt of the therapy and documented clinical benefit (examples include improved pulmonary function, endurance, functional capacity, or reductions in organ volumes depending on agent). The policy also clarifies certain exclusions, such as that Lamzede and Xenpozyme are not covered for CNS manifestations, and cites pivotal trial data supporting pulmonary and functional improvements for these agents.
March 2026 Revision: Consolidated Criteria for Enzyme Replacement Therapies
This revision (effective 2026-03-01) consolidates and restates UnitedHealthcare's medical necessity criteria for multiple enzyme replacement therapies used in lysosomal storage disorders with respiratory manifestations under MDC 04: Pulmonology. The document clarifies initial and continuation authorization lengths (initial and reauthorization limited to no more than 12 months) across several agents including Aldurazyme (laronidase), Elaprase (idursulfase), Lamzede (velmanase alfa-tycv), Mepsevii (vestronidase alfa-vjbk), and Xenpozyme (olipudase alfa-rpcp).
The update explicitly ties coverage to diagnostic confirmation (enzyme assay or molecular genetic testing) and the presence of clinical signs and symptoms for each indicated disorder. For continuation of therapy, the policy reiterates the requirement that the patient has previously received the specified therapy and demonstrated a positive clinical response (examples provided differ by agent and include improved pulmonary function among other outcomes). Dosing is repeatedly required to be consistent with U.S. FDA-approved labeling.
Diagnostic and Clinical Eligibility Requirements by Agent and Indication
The policy defines specific diagnostic confirmation requirements for covered indications. For Aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I), confirmation may be by deficient alpha-L-iduronidase enzyme activity in fibroblasts or leukocytes or by molecular genetic confirmation of mutations in the alpha-L-iduronidase gene. For Elaprase (idursulfase) in MPS II, confirmation requires deficiency in iduronate 2-sulfatase enzyme activity (with normal activity of another sulfatase) or molecular genetic testing for mutations in the iduronate 2-sulfatase gene. For (vestronidase alfa-vjbk) in MPS VII, confirmation may be absence or deficiency of beta-glucuronidase enzyme activity or molecular confirmation of gene mutations.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.